Sweis AM, Locke TB, Ig-Izevbekhai KI, et al. - Between July 2016 and June 2019, researchers conducted this retrospective review to identify the number of patients with aspirin-exacerbated respiratory disease (AERD) who tolerated aspirin therapy, yet due to persistent symptoms, incorporated type 2 (T2) biologic management. The study included patients with AERD who had endoscopic sinus surgery (ESS), aspirin desensitization (AD), and at least 6 months of aspirin therapy (ATAD) after AD, and who remained biologic-naive up through this timepoint. A total of 103 patients met the requirements for inclusion.ESS, in combination with AD and ATAD, was effective in the long-term treatment of the majority of patients with AERD, and T2 biologics were only used in a limited number of cases. Patient questionnaires, such as outcomes measure test score, may help clinicians recognise aspirin therapy failures and decide whether to add T2 biologics to the patient's treatment plan.